Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis

ConditionTuberculosis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age1-18
SponsorBeijing Children's Hospital

About this trial

This study is based on the hypothesis that the pharmacokinetics of anti-tuberculosis drugs in TB children are different from adults. The investigators aim to study the population pharmacokinetics of children receiving the anti-tuberculsis drugs for treatment of TB. In this study, the investigators will detect drug concentration in plasma by using residual blood samples of blood gas analysis and other clinical tests and employ computers for constructing population pharmacokinetic models. In addition, the investigators also want to correlate use of anti-tuberculsis drugs with treatment effectiveness and incidence of adverse effects in children. This novel knowledge will allow better and more rational approaches to the treatment of TB in children. It will also set the foundation for further studies to improve anti-tuberculosis drug therapies for children.

Eligibility criteria

Qualifiers

Children (0-18 years old) with anti-tuberculosis therapy against TB.

The anti-tuberculsis therapy includes drugs commonly used in children infectious diseases

Informed consent signed by the parents and/or guardians.

Disqualifiers

Anti-tuberculosis drugs aren't involved in the therapies of children.

It is unable to provide complete medical records or the current condition cannot accept the study process.

Patients are allergic to anti-tuberculsis drugs.

Parents and/or guardians do not agree to participate in this study.

Trial design

Treatments tested in this trial

  • anti-tuberculosis drug

Treatment groups

No treatment groups listed

Sponsors and collaborators

Beijing Children's Hospital

Lead sponsor

Shandong University

Collaborator

Hopital Universitaire Robert-Debre

Collaborator

Rennes University Hospital

Collaborator